タラタマブ（Imdelltra）、再発小細胞肺がんでFDA完全承認｜生存期間を5.3か月延長 | STELLANEWS.LIFE Amgenのタラタマブ（Imdelltra）が、広範期小細胞肺がんに対する第3相試験で全生存期間を有意に延長し、FDAの完全承認を取得。DLL3標的の二重特異性抗体として新たな治療選択肢に。

FDA grants full approval to Amgen’s Imdelltra (tarlatamab) for relapsed extensive-stage small cell lung cancer (ES-SCLC).

🔗 Full article: stellanews.life/technology_c...

#Imdelltra #Tarlatamab #Amgen #SCLC #Oncology #DLL3 #FDAApproval #Immunotherapy #ClinicalTrials

【タラタマブ（Imdelltra）、再発小細胞肺がんでFDA完全承認】
アムジェンのDLL3標的二重特異性T細胞誘導抗体タラタマブ（Imdelltra）が、
広範期小細胞肺がん（ES-SCLC）を対象にFDAの完全承認を取得。

#タラタマブ #Imdelltra #小細胞肺がん #Amgen #DLL3 #二重特異性抗体 #FDA承認 #DeLLphi304 #免疫療法

Stephen V Liu: DLL3 Expression in EGFR NSCLC after SCLC Transformation - OncoDaily Stephen V Liu: DLL3 Expression in EGFR NSCLC after SCLC Transformation / cancer, Carlos J. Suarez, Farshad Moradi, Gerald J. Berry, Heather A. Wakelee,

DLL3 Expression in EGFR NSCLC after SCLC Transformation - Stephen V Liu

@stephenvliu.bsky.social

oncodaily.com/voices/steph...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DLL3 #NSCLC #SCLC #LungCancer

This study provides insights into NECC treatment through a novel in-vitro #3DOrganoids-TILs co-culture system targeting #DLL3, highlighting its potential as a therapeutic avenue with clinical implications. @fudanuni_official #medsky
#OpenAccess:
www.sciencedirect.com/science/arti...

One final note: You'll notice that in the RNAseq data of PDXs/PDOs, there's another target we highlighted #DLL3, which is also expressed in SCLC and NEPC and is being pursued as a target for these cancers including #radiotheranostics

doi.org/10.1016/S147...

This study explores patient-reported outcomes #PROs for patients with previously treated #SCLC receiving #Tarlatamab, a bispecific T-cell engager binding #DLL3 and #CD3

@natureportfolio.nature.com

#Onco404 #Cancer #Kanser #LungCancer #ClinicalTrials #Immunotherapy #BispesificAntibody #MedSky

IDEAYA Biosciences Receives FDA Clearance for IDE849 Drug Development Targeting Solid Tumors IDEAYA Biosciences has received FDA IND clearance for IDE849, a promising drug targeting DLL3 in solid tumors, including SCLC and NETs.

IDEAYA Biosciences Receives FDA Clearance for IDE849 Drug Development Targeting Solid Tumors #USA #IDEAYA_Biosciences #South_San_Francisco #IDE849 #DLL3

COOL! Prof #Renier_Brentjens @roswellpark.bsky.social #Cancer #Center/ #CAR_T #immunotherapy to #DLL3 using scFvs /SC16.8 cures #SCLC in mice without #lymphodepletion #Bridge2024 @sitcancer.bsky.social @egfrpositiveuk.bsky.social @alkpositiveuk.bsky.social @cruk-mi.bsky.social #SmallCellLungCancer